[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-stress-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-stress-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,77,104,128,161,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641098","early-intervention-to-prevent-development-of-ptsd-in-burn-survivors-and-their-caregivers-100641098",false,"NCT07656545","Early Intervention to Prevent Development of PTSD in Burn Survivors and Their Caregivers","Inclusion Criteria:\n\n* Alert, oriented, \\& not withdrawing from substance at time of screening\n* Can read and write in English\n* Hospitalized within 10 days of burn injury\n* Anticipated discharge \\\u003C=4 weeks\n* Have an email, mailing address, and at least 1 smart device for telehealth sessions\n* PTSD risk score of 2 or greater (patient-only)\n* Willing to attend therapy sessions with a loved one\n\nExclusion Criteria:\n\n* Currently incarcerated or in police custody\n* \\> 10 days post-burn\n* Lifetime diagnosis of primary psychosis or intellectual disability\n* Ongoing reported domestic violence in the dyad\n* Unstable bipolar disorder, severe substance use disorder, or acute suicidality with imminent intent that does not remit within 10 days of burn-injury\n* Inflammation Confounds (patient-only) of BMI \\> 40, metabolic syndrome, admission A1C of \\>= 6.5%\n* Currently receiving couples therapy",true,"ALL","18 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this clinical trial is to adapt and test a brief patient-caregiver early intervention designed to reduce posttraumatic stress symptoms in hospitalized burn patients and their caregivers. This intervention is a brief, 4-session cognitive-behavioral intervention designed for burn patients and their loved one to complete together, during and after hospitalization. The intervention targets relational communication and functioning through reduction of invalidating, negative statements and avoidant coping by teaching patients and their loved ones to engage in adaptive natural disclosures, supportive responses, and approach coping after the burn trauma. The intervention uses evidence-based psychotherapy techniques, including psychoeducation, motivational interviewing, and skills coaching. The clinical trial will occur in two sequential phases. In the first phase of the study (case series), the intervention will be provided to two burn patient-caregiver dyads (four adults) to pilot test the intervention, seek patient and provider feedback, and refine the intervention. All four adults will receive the intervention. In the second phase of the study, the randomized controlled trial (RCT) phase, investigators will enroll 20 more burn patient-caregiver dyads (40 more adults) who will be randomly assigned (like the flip of a coin) at the dyad level to receive the intervention or a burn survivor-only minimally enhanced usual care psychoeducation control condition (mEUC). The goals of the RCT phase are to study whether the intervention is acceptable to patients, feasible to conduct, and whether the intervention improves burn survivor-caregiver healthy relationship communication about difficult events and treatment outcomes compared to mEUC.",[26,27,28,29,30,31,32,33,34,35,36],"Posttraumatic Stress Disorder","Burns","Traumatic Injury","Acute Stress Disorder","Trauma and Stressor Related Disorders","Trauma and Stress Related Disorders","Stress Disorder","Stress Disorders, Post-Traumatic","Stress Disorders, Traumatic","Stress Disorders, Traumatic, Acute","Relationship, Social","NOT_YET_RECRUITING","2026-06-14",{"date":40,"type":41},"2026-06-18","ACTUAL",{"date":43,"type":20},"2026-08-01",{"date":45,"type":20},"2029-02-28",{"name":47,"class":48},"University of Southern California","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":15,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100608124","adolescent-stress-and-substance-intervention-subsequent-to-trauma-100608124","NCT07197476","Adolescent Stress and Substance Intervention Subsequent to Trauma","Adolescent Injury: Intervening to Prevent Posttraumatic Stress and Substance Use Outcomes","ASSIST","Inclusion Criteria for Youth:\n\n* Must be 12-17 years\n* Fluent in English or Spanish\n* Able to provide informed assent\n* Have a parent able to provide informed consent\n\nInclusion Criteria for Parents:\n\n* Live with an admitted pediatric trauma patient\n* Fluent in English or Spanish\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Prisoner or in police custody\n* Involvement with child protective services\n* Admitted due to suicide attempt or non-suicidal self-injury\n* Any acute condition that would preclude provision of informed consent or assent","12 Years","17 Years",{"count":61,"type":20},92,[23],"The long-term goal of this study is to address the adoption of the new trauma center requirement to establish best practices of screening for acute stress with an intervention to prevent both adolescent PTSD and substance use. The investigators will develop, refine, and pilot test the Adolescent Stress and Substance Intervention Subsequent to Trauma (ASSIST) video interventions that build upon the American College of Surgeons Committee on Trauma guidelines to improve mental health care during and after hospitalization for traumatic injury. The aims are:\n\nPHASE I - Primary Aim 1: To develop and refine two ASSIST video interventions for adolescents and parents admitted to a level 1 pediatric trauma center.\n\nPHASE II\n\n* Primary Aim 2a: To evaluate the feasibility, acceptability and implementation potential of the ASSIST video interventions.\n* Primary Aim 2b: Develop the ASSIST implementation protocol using a national advisory panel of pediatric trauma center leaders.\n\nParticipants in PHASE 1:\n\nParent and child duo:\n\n* Review storyboards for the video interventions\n* Participate in qualitative interviews at hospital admission and 1 month following discharge\n\nPediatric trauma center clinical staff members:\n\n\\- Complete qualitative interviews\n\nParticipants in PHASE II:\n\nParent and child duo:\n\n* Shown their own video interventions\n* Complete assessments at admission and 1-, 2-, 3- months after discharge",[65,66,29],"PTSD","Substance Use Disorder (SUD)","RECRUITING","2026-04-27",{"date":70,"type":41},"2026-04-28",{"date":72,"type":41},"2026-03-03",{"date":74,"type":20},"2027-04",{"name":76,"class":48},"Rhode Island Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100588592","phase-2-bxcl501-after-stress-to-increase-recovery-success-100588592","NCT06943404","BXCL501 After Stress to Increase Recovery Success","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)","RISE","Inclusion Criteria:\n\n1. ≥ 18 years and ≤ 65 years of age\n2. Admitted to ED within 72 hours of MVC\n3. Anticipated to be discharged home from the ED\n4. Stated willingness to comply with all study procedures and availability for the duration of the study\n5. Consent to receive unencrypted communications\n6. Has a smartphone with continuous service for ≥ 1 year\n7. Has a personal email address they regularly access\n8. Able to speak and read English\n9. Females of childbearing potential (not surgically sterilized (tubal ligation\u002Fhysterectomy) or not post-menopausal (no menstrual period for \\> 12 months)) must be willing to use a medically acceptable and effective birth control method for 3 months before the study and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills or patches, birth control implants, diaphragm, intrauterine device (IUD), or condoms\n\nExclusion Criteria:\n\n1. Substantial comorbid injury (e.g., long bone fracture)\n2. People of childbearing potential who are pregnant, breastfeeding, planning to become pregnant, or not using a highly effective form of contraception (e.g., implants, intrauterine devices (IUDs), tubal ligation, hormonal birth control pills, patches, vaginal rings, or injections) during their participation\n3. Prisoner status\n4. Chronic daily opioid use prior to MVC (\\> 20 mg oral daily morphine equivalents)\n5. Bipolar disorder, psychotic disorder, active psychosis, suicidal ideation, or homicidal ideation\n6. Hospital admission\n7. Clinically significant history of cardiac disease including (a) history of syncope or other syncopal attacks; (b) current evidence of orthostatic hypotension (defined as a decrease in systolic BP of 20 mm Hg or decrease in diastolic BP of 10mm Hg within 3 minutes); (c) resting heart rate of \\\u003C55 beats per minute; (d) systolic blood pressure \\\u003C110mmHg or diastolic BP \\\u003C70mmHg; (e) participants with a QTC interval \\>440msec (males) or \\>460msec (females) not in sinus rhythm; or 1st, 2nd or 3rd degree hearth block; or (f) history of severely impaired ventricular function (ejection fraction \\\u003C 30%).\n8. Hypomagnesia (\\\u003C1.7 mg\u002FdL) or hypokalemia (\\\u003C 3.0 mEq\u002FL)\n9. Substantial hepatic impairment (e.g. AST or ALT \\> 3 times the upper limit of normal or history of cirrhosis).\n10. Currently taking the following medications: a) medications for alcoholism (e.g. naltrexone, disulfiram, topiramate, acamprosate); b) psychotropic medications that promote sedation including sedative\u002Fhypnotics, barbiturates, antihistamines, sedative antidepressants (e.g. doxepin, mirtazapine, trazodone), and triptans (e.g., sumatriptan); c) alpha-2-adrenergic agonists (clonidine, guanfacine, lofexidine); d) adrenergic agents prescribed for other reasons (prazosin); e) or medications known to cause QT prolongation. (Permitted Concomitant Medications: The concomitant medications allowed in the study include non-sedative antidepressants used to treat PTSD)\n11. Hypersensitivity or history of allergic reaction to dexmedetomidine\n12. Lacking capacity to provide informed consent (receipt of sedative, hypnotic agent making the patient non-decisional for consent)\n13. Any other history or condition that would, in the site investigator's judgement, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger patient)\n14. Participation in any other clinical trial of a pharmacological agent within 30 days prior to screening.","65 Years",{"count":87,"type":20},100,[89],"PHASE2","This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats\u002Freduces ASR\u002FASD symptoms (primary outcome), improves neurocognitive function, and prevents\u002Freduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 100 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.",[92,29,93],"Acute Stress Reaction","Post-traumatic Stress Disorder","2026-04-09",{"date":96,"type":41},"2026-04-14",{"date":98,"type":41},"2026-02-23",{"date":100,"type":20},"2026-09-29",{"name":102,"class":48},"University of North Carolina, Chapel Hill",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100565023","phase-2-preventionreduction-of-asrs-and-ptsd-to-sustain-civilian-performance-with-sublingual-cyclobenzaprine-hcl-tnx-102-sl-100565023","NCT06636786","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)","Prevention\u002FReduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)","OASIS","Inclusion Criteria:\n\n1. ≥ 18 years and ≤ 55 years of age\n2. Presentation to ED within 72 hours of MVC\n3. Anticipated to be discharged home from the ED\n4. Stated willingness to comply with all study procedures and availability for the duration of the study\n5. Consent to receive unencrypted communications\n6. Has a smartphone with continuous service for ≥ 1 year\n7. Has a personal email address they regularly access\n8. Able to speak and read English\n9. Pain severity in the ED ≥ 4 (0-10 numeric rating scale)\n10. People who are not of childbearing potential (e.g., hysterectomy, bilateral oophorectomy, or confirmed postmenopausal for at least last 12 consecutive months)\n11. People with the capacity to conceive a pregnancy must agree to employ a highly effective form of birth control throughout the first 21 days of study participation (e.g., oral, injected, transdermal, or implanted hormonal methods of contraception for at least one full menstrual cycle prior to study drug administration; placement of an intrauterine device (IUD) or intrauterine system (IUS); or double barrier methods such as condoms and diaphragms)\n\nExclusion Criteria:\n\n1. Substantial comorbid injury (e.g., long bone fracture)\n2. People of childbearing potential who are pregnant, breastfeeding, planning to become pregnant, or not using a highly effective form of contraception (e.g., implants, intrauterine devices (IUDs), tubal ligation, hormonal birth control pills, patches, vaginal rings, or injections) during their participation\n3. Prisoner status\n4. Any chronic daily opioid use prior to MVC\n5. Active psychosis, suicidal ideation, or homicidal ideation\n6. Plans for hospital admission\n7. History of arrhythmias, heart block or conduction disturbances, congestive heart failure\n8. Currently in the acute recovery phase of myocardial infarction\n9. Hypersensitivity to cyclobenzaprine or the excipient in TNX-102 SL or placebo formulations\n10. History of urinary retention, angle-closure glaucoma, increased intraocular pressure, or hyperthyroidism (TSH \\\u003C lower limit of normal)\n11. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation due to risk of potential fatal drug-drug interactions\n12. Current or planned use of the following prohibited concomitant medications during study participation: anticholinergic medications, guanethidine, selective serotonin reuptake inhibitors (SSRIs) , serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, MAO inhibitors, anticholinergic medications, guanethidine, potent cytochrome P450 subtype 3A4 inhibitor, St. John's wort, chronic use muscle relaxants or planned use after MCV or other prohibited concomitant medications listed in section 5.6. PI to assess individual cases where single dose of muscle relaxant is prescribed in ED for inclusion\n13. Any hepatic impairment or renal disease (defined as AST OR ALT \\> 3 times the upper limit of normal) or renal disease (defined as GFR ≤ 80 mL\u002Fmin)\n14. Lacking capacity to provide informed consent (receipt of sedative, hypnotic agent making the patient non-decisional for consent)\n15. Any other history or condition that would, in the site investigator's judgement, indicate that the patient would very likely be non-compliant with the study or unsuitable for the study (e.g., might interfere with the study, confound interpretation, or endanger patient)\n16. Elevated baseline blood pressure defined as systolic blood pressure ≥ 170 mmHg or diastolic blood pressure ≥ 100 mmHg and or elevated heart rate of ≥115\n17. Abnormal baseline ECG as defined as: QRS duration ≥ 120 ms; QTc \\> 460 ms; not in sinus rhythm; or 1st, 2nd, or 3rd degree heart block indicated\n18. Substance or alcohol use disorder, bipolar disorder, or schizophrenia\n19. History of severe or unexplained oral, or oropharyngeal swelling or edema","55 Years",{"count":114,"type":20},180,[89],"This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled randomized clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats\u002Freduces acute stress reaction (ASR)\u002Facute stress disorder (ASD) symptoms (primary outcome), improves neurocognitive function, and prevents\u002Freduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 180 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.",[92,29,118,119],"Neurocognitive Function","Post-traumatic Stress",{"date":121,"type":41},"2026-04-13",{"date":123,"type":41},"2025-03-25",{"date":125,"type":20},"2026-09",{"name":102,"class":48},9,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":147,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":49},"100472117","respiratory-training-in-the-treatment-of-transdiagnostic-pathological-anxiety-100472117","NCT05427708","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety","Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Clinically elevated anxiety as indicated by an eight or higher on the Overall Anxiety Severity and Impairment Scale (OASIS).\n2. Meets DSM-5 criteria for one or more of the following anxiety or trauma-related disorders as their \"primary\" mental disorder:\n\n   * Generalized Anxiety Disorder\n   * Panic Disorder\n   * Health Anxiety\n   * Agoraphobia\n   * Social Anxiety Disorder\n   * Posttraumatic Stress Disorder\n   * Acute Stress Disorder\n   * Adjustment Disorder with primary anxious mood\n   * Anxiety disorder not otherwise specified\n3. No current use of psychotropic medications or stable on current medications for at least 6 weeks\n4. Age 18+.\n5. Able to arrange transportation to our laboratory for study appointments.\n6. Fluent in English.\n\nExclusion Criteria:\n\n1. No history of medical conditions that would contraindicate participation in fear-provocation or respiratory challenges, including:\n\n   * Cardiovascular or respiratory disorders\n   * High blood pressure\n   * Epilepsy\n   * Strokes\n   * Seizures\n   * History of fainting\n   * Pregnant or lactating\n2. Not currently receiving other psychological treatment for anxiety.\n3. No history of a suicide attempt within the past 6 months.\n4. No history of psychosis within the past 6 months.\n5. No history of moderate to severe alcohol or substance use disorder (with the exception of nicotine) within the past 3 months.\n6. Does not endorse COVID-19 symptoms during the screening phase.",{"count":114,"type":20},[23],"Purpose of the Research: The primary aim of the proposed study is to conduct a randomized parallel-group 2-arm clinical trial investigating capnometry-guided respiratory intervention (CGRI) for pathological anxiety. CGRI aims to raise end-tidal CO2 levels thereby lowering hyperventilation-induced respiratory alkalosis and its associated fear-eliciting somatic reactions. Psycho-education about anxiety and its effects (PsyEd) will serve as a credible control comparator.",[139,140,141,142,143,144,145,26,29,146],"Anxiety Disorders","Trauma","Generalized Anxiety Disorder","Panic Disorder","Agoraphobia","Illness Anxiety Disorder","Social Anxiety Disorder","Adjustment Disorder With Anxious Mood",[148,149,150,151],"Psychoeducation","Respiratory training","Transdiagnostic","Intervention","2025-08-18",{"date":154,"type":41},"2025-08-24",{"date":156,"type":41},"2022-08-22",{"date":158,"type":20},"2027-05",{"name":160,"class":48},"University of Texas at Austin",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":49},"100554670","internet-delivered-trauma-focused-cognitive-behavioral-therapy-as-an-early-intervention-after-sexual-trauma-100554670","NCT06502106","Internet-delivered Trauma-focused Cognitive-behavioral Therapy as an Early Intervention After Sexual Trauma","Inclusion Criteria:\n\n* Experienced trauma in the past two months according to criterion A for PTSD in the DSM-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence).\n* At least mild clinical symptoms assessed using the PCL-5 cut-off \\>10\n* ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk)\n* Unable to read and write in Swedish\n* Receiving other psychological trauma-focused treatment\n* Ongoing trauma-related threat (e.g., living with a violent spouse)\n* Not stable dose of antidepressant medication the last two weeks",{"count":168,"type":20},30,[23],"The research aims to assess the practicality and implementation aspects, effectiveness, and processes of change related to Condensed Internet-delivered Prolonged Exposure (CIPE) administered as an early trauma focused intervention after sexual assault. Eligible participants are individuals seeking help at Traumamottagning Centrum för Sexuell Hälsa, Malmö who have been exposed to sexual assualt in the past two months and exhibit psychological symptoms in response to that.",[29,172],"Post Traumatic Stress Disorder",[174,65,175,176,177,178,179],"condensed prolonged exposure","internetdelivered","trauma","early intervention","prevention","CIPE","2024-07-09",{"date":182,"type":41},"2024-07-16",{"date":184,"type":20},"2024-10",{"date":186,"type":20},"2025-10",{"name":188,"class":48},"Karolinska Institutet",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":49},"100540542","condensed-digital-prolonged-exposure-for-individuals-treated-within-somatic-trauma-care-100540542","NCT06318195","Condensed Digital Prolonged Exposure for Individuals Treated Within Somatic Trauma Care.","Internet Delivered Condensed Cognitive Behavioral Treatment (Prolonged Exposure) for Individuals Treated Within Somatic Trauma Care.","CiPE","Inclusion Criteria:\n\n* Exposed to trauma in the past two months according to criterion A for PTSD in the DSM-5 (exposed to death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence).\n* PCL-5 total sum score\\>10\n* ≥ 18 years\n* Situated in Sweden\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other serious comorbidity as primary concern (ongoing substance dependence, untreated bipolar disorder, psychotic symptoms, severe depression, borderline personality disorder, high suicidal risk according to the MINI)\n* Unable to read and write in Swedish\n* Receiving other psychological trauma-focused treatment\n* Ongoing trauma-related threat (e.g., living with a violent spouse)\n* Not stable dose of antidepressant medication the last two weeks",{"count":198,"type":20},250,[23],"The purpose of the study is to investigate the feasibility of implementation aspects, treatment effects and change processes regarding a brief trauma-focused Internet-based CBT treatment, for patients who have been treated in trauma care at Karolinska University Hospital and who exhibit symptoms of psychological consequences of the traumatic event. Another aim is to explore factors (predictors, moderators and mediators) that influence the effect of the treatment, in order to better understand who responds to the treatment.",[172,29],[174,203,65,176,177,178,179],"Internet-delivered",{"date":205,"type":41},"2024-07-10",{"date":207,"type":20},"2024-09",{"date":209,"type":20},"2026-08",{"name":188,"class":48}]